Reuters logo
BRIEF-PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient
November 14, 2017 / 9:20 AM / 7 days ago

BRIEF-PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient

Nov 14 (Reuters) - PAION AG

* ‍FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN U.S. AS SUFFICIENT

* ‍NO SECOND INTRANASAL STUDY REQUIRED​

* ‍ASSUMES CLINICAL DEVELOPMENT PROGRAM FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN U.S. AS COMPLETED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below